Skip to content
10-Q

Quarterly Report

SCPHARMACEUTICALS INC.

0000950170-24-097002

← back to feed
Filed
Aug 14, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Aug 13, 2024 50.03M sh
Long Term Debt Q2 2024 · Jun 30, 2024 $39.99M
Long Term Debt Q2 2024 · Dec 31, 2023 $38.81M
Cash And Equivalents Q2 2024 · Jun 30, 2024 $38.5M
Cash And Equivalents Q2 2024 · Dec 31, 2023 $46.81M
Current Liabilities Q2 2024 · Jun 30, 2024 $12.93M
Current Liabilities Q2 2024 · Dec 31, 2023 $13.13M
Total Liabilities Q2 2024 · Jun 30, 2024 $56.21M
Total Liabilities Q2 2024 · Dec 31, 2023 $57.26M
Current Assets Q2 2024 · Jun 30, 2024 $62.63M
Current Assets Q2 2024 · Dec 31, 2023 $92.94M
Total Assets Q2 2024 · Jun 30, 2024 $65.46M
Total Assets Q2 2024 · Dec 31, 2023 $94.48M
Short Term Investments Q2 2024 · Dec 31, 2023 $29.2M
Shares Diluted Q2 2024 · Jun 30, 2023 38.69M sh
Shares Diluted Q2 2024 · Jun 30, 2023 38.25M sh
Capex Q2 2024 · Jun 30, 2023 $3K
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$30.64M
Stockholders Equity Q2 2024 · Jun 30, 2023 $63.43M
Stockholders Equity Q2 2024 · Mar 31, 2023 $75.81M
Stockholders Equity Q2 2024 · Dec 31, 2022 $72.43M
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.36
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.66
Eps Basic Q2 2024 · Jun 30, 2023 −$0.36
Eps Basic Q2 2024 · Jun 30, 2023 −$0.66
Sga Expense Q2 2024 · Jun 30, 2023 $12.1M
Sga Expense Q2 2024 · Jun 30, 2023 $22.99M
Rd Expense Q2 2024 · Jun 30, 2023 $2.93M
Rd Expense Q2 2024 · Jun 30, 2023 $5.05M
Net Income Q2 2024 · Jun 30, 2023 −$14.15M
Net Income Q2 2024 · Jun 30, 2023 −$25.36M
Operating Income Q2 2024 · Jun 30, 2023 −$13.75M
Operating Income Q2 2024 · Jun 30, 2023 −$25.3M
Cost Of Revenue Q2 2024 · Jun 30, 2023 $354K
Cost Of Revenue Q2 2024 · Jun 30, 2023 $959K
Revenue Q2 2024 · Jun 30, 2023 $1.64M
Revenue Q2 2024 · Jun 30, 2023 $3.7M